Dual effects of Rho-kinase inhibitors on a rat model of inflammatory pain by Paiva-Lima, P et al.
Pain Res Manag Vol 19 No 6 November/December 2014e172
Dual effects of Rho-kinase inhibitors on a  
rat model of inflammatory pain
Patricia Paiva-Lima PhD1, YS Bakhle PhD2, Janetti N Francischi PhD1
1Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; 
2Leukocyte Biology, National Heart and Lung Institute, Faculty of Medicine, Imperial College, London, United Kingdom
Correspondence: Prof Janetti N Francischi, Departamento de Farmacologia, ICB-UFMG, Av. Antônio Carlos 6627, Pampulha, Belo Horizonte, 
Minas Gerais 31901-270, Brasil. Telephone 55-31-34092527, fax 55-31-34092695, e-mail janettif@icb.ufmg.br
Rho-kinase (ROCK) is a serine/threonine kinase identified as a GTP-Rho-binding protein belonging to the family of GTPases 
(1). Although many studies have focused on ROCKs in smooth 
muscle cells (2,3), many other activities have been associated with 
ROCKs in other cellular systems (3-5). Particularly, the participation 
of ROCKs in platelet aggregation, formation of stress fibres, focal 
adhesion, cellular motility (6-9) and monocyte transendothelial 
migration (10) has been described, which, collectively, suggest the 
involvement of ROCKs in inflammatory processes (11-13). Closer to 
the present context, ROCK activity has also been implicated in pain 
sensitivity responses such as those stimulated by cold (14), heat 
(15,16), formalin (17) and other stimuli (18-20). In addition, ROCKs 
have been implicated in the inhibition of acetylcholine release in 
peripheral cholinergic nerves (21). 
In terms of underlying mechanisms, ROCK activity modifies cyto-
skeletal structure and function by metabolism of intermediary fila-
ments (vimentin [8]); phosphorylation of myristoylated alanine-rich 
C-kinase substrate (22); or, especially, via binding proteins that regu-
late microfilament polymerization (5,23,24). The imbalance in cyto-
skeleton assembly caused by ROCK activation may interfere in crucial 
functions of the central nervous system (19) including inflammatory 
and neuropathic pain (22). Accordingly, ROCK inhibition increased 
neurite outgrowth (17,24,25), an important aspect of the cytoskeleton 
associated with augmented pain sensitivity (26); conversely, its dis-
turbance was reflected in a decrease in the pain sensitivity response 
(15). Another mechanistic link between ROCKs and nociception 
(17) is their with the phosphorylation cascade of cofilin, an actin-
destabilizing protein (27), which implies an important role 
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BackgRouND: Rho-kinases (ROCKs), a family of small GTP-
dependent enzymes, are involved in a range of pain models, and their 
inhibition typically leads to antinociceptive effects.
oBJectiveS: To study the effects of inhibiting ROCKs using two 
known inhibitors, Y27632 and HA1077 (fasudil), administered locally, on 
nociception and paw edema in rats.
MethoDS: A range of doses of Y27632 or HA1077 (2.5 μg to 1000 μg) 
were injected locally into rat paws alone or in combination with carra-
geenan, a known proinflammatory stimulus. Nociceptive responses to 
mechanical stimuli and increased paw volume, reflecting edema formation, 
were measured at 2 h and 3 h, using a Randall-Selitto apparatus and a 
hydroplethysmometer, respectively.
ReSuLtS: Animals treated with either ROCK inhibitor showed biphasic 
nociceptive effects, with lower doses being associated with pronociceptive, 
and higher doses with antinociceptive responses. In contrast, a monopha-
sic dose-dependent increase in edema was observed in the same animals. 
Local injection of 8-bromo-cyclic (c)GMP, an activator of the nitric oxide/
cGMP/protein kinase G pathway, also produced biphasic effects on noci-
ceptive responses in rat paws; however, low doses were antinociceptive and 
high doses were pronociceptive. Local administration of cytochalasin B, an 
inhibitor of actin polymerization and a downstream mediator of ROCK 
activity, reversed the antinociceptive effect of Y27632.
coNcLuSioNS: The results of the present study suggest that ROCKs 
participate in the local mechanisms associated with nociception/
antinociception and inflammation, with a possible involvement of the 
nitric oxide/cGMP/protein kinase G pathway. Also, drug effects following 
local administration may differ markedly from the effects following sys-
temic administration. Finally, separate treatment of pain and edema may 
be needed to maximize clinical benefit in inflammatory pain.
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Les doubles effets des inhibiteurs de la  
rho-kinase sur un modèle murin de douleur 
inflammatoire
hiStoRiQue : Les rho-kinases (ROCK), une famille de petits enzymes 
GTPases, participent à une série de modèles de douleur, et leur inhibition 
a généralement des effets antinociceptifs.
oBJectiFS : Étudier les effets de l’inhibition des ROCK au moyen de 
deux inhibiteurs connus administrés localement, le Y27632 et le HA1077 
(fasudil), sur la nociception et l’œdème des pattes des rats.
MÉthoDoLogie : Les chercheurs ont injecté une série de doses de 
Y27632 et de HA1077 (de 2,5 μg à 1 000 μg) dans les pattes de rats, 
seules ou en combinaison avec de la carraghénane, un stimulant pro-
inflammatoire connu. Ils ont mesuré les réponses nociceptives aux stimuli 
mécaniques et à l’augmentation du volume des pattes, reflétant la forma-
tion d’œdème au bout de deux et trois heures, au moyen d’un test de 
Randall-Selitto et d’un hydro-pléthysmomètre, respectivement.
RÉSuLtatS : Les animaux traités avec l’un des inhibiteurs de la ROCK 
ont présenté des effets nociceptifs biphasiques, les doses moins élevées 
s’associant à une réponse pronociceptive et les doses plus élevées, à une 
réponse antinociceptive. Par contre, chez les mêmes animaux, on a observé 
une augmentation monophasique de l’œdème associée à la dose. L’injection 
locale de cGMP 8-bromo-cyclique, un activateur du monoxyde d’azote, du 
cGMP et de la voie de protéine kinase G, produisait également des effets 
biphasiques sur les réponses nociceptives des pattes de rats. Cependant, de 
faibles doses étaient antinociceptives et de fortes doses, pronociceptives. 
L’administration locale de cytochalasine B, un inhibiteur de la polymérisa-
tion de l’actine et un médiateur en aval de l’activité des ROCK, renversait 
l’effet antinociceptif du Y27632.
coNcLuSioNS : D’après les résultats de la présente étude, les ROCK 
participent aux mécanismes locaux associés à la nociception ou à 
l’antinociception et à l’inflammation, peut-être en association avec le 
monozyde d’azote, le cGMP et la voie de la protéine kinase G. De plus, les 
effets des médicaments après leur administration locale peuvent différer 
considérablement de ceux consécutifs à leur administration systémique. 
Enfin, un traitement distinct de la douleur et de l’œdème peut s’imposer 
pour en maximiser les avantages cliniques en cas de douleur inflammatoire.
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in nociception mediated via the nitric oxide (NO)/cyclic (c)GMP/
protein kinase G (PKG) pathway. Other NO-ROCK interactions lead 
to a stimulatory activity of ROCKs on NO synthesis (28) and the 
inverse, activation of ROCK production by NO (29). Thus, although 
ROCK-NO interactions have been demonstrated, the mechanisms 
underlying these interactions are not completely understood. The NO/
cGMP/PKG pathway is an important component of the peripheral 
analgesic effects associated with a range of known analgesic com-
pounds (30-39). Despite the well-documented analgesic or, more 
properly, antinociceptive effects related to this cGMP pathway, noci-
ceptive as well as antinociceptive responses have been observed fol-
lowing injections of NO donors, cGMP analogues or L-arginine, 
depending on the dose and agent used (40-45). Because biphasic 
effects are brought about by activation of the cGMP pathway (41,43) 
and by ROCK inhibition (46), and because both pathways could be 
involved in nociceptive responses in the periphery, we have analyzed 
the role(s) played by ROCK inhibitors in a model of peripheral 
nociception. 
We have tested the effects of two ROCK inhibitors, Y27632 and 
HA1077 (fasudil), alone or in combination with carrageenan, a stan-
dard proinflammatory stimulus (47), in a well-established model of 
inflammatory pain (48), assessing both nociception and edema. 
Because most of the work using ROCK inhibitors in vivo cited above 
has used systemic or central administration of these compounds, and 
because we were particularly interested in their peripheral effects, we 
administered the ROCK inhibitors locally, by intraplantar (IPL) injec-
tion. We also examined the inflammatory effects of 8-bromo-cGMP, a 
cGMP analogue, to assess the contribution of the NO/cGMP/PKG 
pain pathway to this model and investigated the participation of the 




All animal care and experimental procedures conformed to the regula-
tions of the International Association for the Study of Pain on Ethical 
Issues and were approved by the Federal University of Minas Gerais 
Ethics Committee for Animal Use (Belo Horizonte, Brazil). Male 
Holtzman rats (150 g to 180 g) were supplied by the Bioterism Center 
of the Federal University of Minas Gerais. The animals were housed in 
groups of five animals with a 12 h light/12 h dark cycle and temper-
ature of 24±2°C. They were allowed access to commercial food and 
water ad libitum. In the first experiment, groups of rats (n=3 to n=5) 
were injected with Y27632 (2.5 μg to 1000 μg), HA1077 (25 μg to 
500 μg), 8-bromo-cGMP (25 μg to 1000 μg) or vehicle (2% dimethyl 
sulfoxide in saline) IPL at time zero. In a second experiment, groups of 
animals (n=5) were injected with Y27632 (25 μg or 500 μg) or vehicle 
5 min before the proinflammatory stimulus (250 μg carrageenan, 
injected IPL), considered to represent time 0. In a third set of experi-
ments, cytochalasin B (1 μg) or vehicle was injected IPL 15 min before 
Y27632 (25 μg or 500 μg; n=3 to n=5).The total volume of all IPL 
injections was never >100 μL and they were administered with sterile 
1 mL syringes and 0.38×13 mm needles. The doses and dilutions of 
drugs and the times of administration used in the experiments were 
based on published data for the ROCK inhibitors (15,18) and for 
8-bromo-cGMP (41,43). 
Measurement of the nociceptive threshold
All assays were performed without knowledge of the treatments admin-
istered to the animals. The nociceptive response was evaluated using a 
pressure algesimeter (Ugo Basile, Italy), in which a progressive compres-
sion is applied to a rat’s hindpaw, essentially as proposed by Randall and 
Sellitto (48). This method consists of the measurement (in g) of the 
force applied to the pads necessary to trigger a defensive behaviour, such 
as hindpaw withdrawal, which is a sign of nociception. To avoid tissue 
damage, the maximum weight applied was fixed at 300 g. The intensity 
of the nociceptive response (Δ nociceptive threshold) was expressed as 
the mean (± SEM) difference between nociceptive thresholds (in g) 
obtained in the right (injected with the test substance) and left 
(injected or not injected with vehicle) paws at each timepoint. The dif-
ference (Δ) of nociceptive thresholds among saline, vehicle and naive-
contralateral paws did not change significantly over the experimental 
period from the values at time 0 (Table 1). 
The nociceptive responses were measured immediately before 
(time 0), and 15 min, 30 min, 60 min and 120 min after administra-
tion of ROCK inhibitors, and also 180 min after carrageenan adminis-
tration. To facilitate data comparison, the results were transformed 
into area under the curve over 120 min or 180 min of observation for 
each group, using the trapezoidal rule from GraphPad Prism version 
6.01 (GraphPad Software, USA). 
assessment of paw edema formation 
Paw volumes of the same animals (see above) were measured using a 
hydroplethysmometer (Ugo Basile, Italy), and data were expressed as 
the difference (Δ) between right and left hindpaws in millilitres (mean 
± SEM) for a group of animals, at the same time points as used in the 
nociceptive threshold experiments. To facilitate data comparison, 
these results were also transformed into the area under the curve using 
the trapezoidal rule, as described above.
chemicals
The compounds Y27632 ([R]-[+]-trans-4-[1-aminoethyl]-N-[4-pyridyl] 
cyclohexanecarboxamide dihydrochloride) and HA1077 (fasudil) 
were purchased from Cayman Chemicals (USA) and LClabs (USA), 
respectively. Cytochalasin B, an inhibitor of actin polymerization 
(49), and 8-bromo-cGMP were purchased from Sigma (USA) and 
λ-carrageenan from Science Lab (USA). All compounds, except car-
rageenan, were dissolved in 1% to 20% dimethyl sulfoxide in sterile 
isotonic saline. Carrageenan was dissolved in sterile isotonic saline.
TABLE 1
Effects of the Rho-kinase inhibitor Y27632 (Y) on 
nociceptive thresholds in rat paws
Treatment/
dose, μg
Nociceptive threshold, g applied/time, min
0 30 60 120 180
Vehicle (n=5)
   RP 134±9 126±15 126±5 128±8 136±9
   LP 138±8 130±12 134±9 132±11 132±8
2.5 μg Y (n=4)
   RP 127±9 117±20 125±13 125±6 130±12
   LP 128±10 127±10 130±12 128±10 128±10
25 μg Y (n=7)
   RP 133±8 83±17 81±13 84±14 101±12
   LP 131±7 129±9 130±8 124±8 130±8
50 μg Y (n=6)
   RP 130±9 88±8 86±20 100±31 125±14
   LP 130±9 133±12 135±12 128±15 130±13
150 μg Y (n=5)
   RP 130±10 124±11 130±7 124±11 128±11
   LP 132±8 126±11 126±9 128±8 130±10
500 μg Y (n=7)
   RP 126±5 197±17 191±31 151±19 131±12
   LP 127±8 128±11 130±10 126±8 133±8
1000 μg Y (n=6)
   RP 127±5 220±32 215±26 178±21 138±22
   LP 125±5 117±5 118±4 123±10 120±6
Data presented as mean ± SD. Animals received vehicle or Y in a volume of 
100 μL injected intraplantarly into animal’s right hind paw (RP). The left hind 
paw (LP) was injected only with vehicle and served as a control. Measurements 
of nociceptive thresholds were performed without knowledge of the treatments
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Statistical analysis
Data for each group of four to seven animals (mean ± SEM) were 
analyzed using one-way ANOVA. Differences between means were 
further examined using Bonferroni’s test. Differences between means 
were considered to be statistically significant at P<0.05.
ReSuLtS
effects of single iPL injections of Rock inhibitors or a cgMP 
analogue on nociceptive threshold and paw edema 
To study the role of the ROCK inhibitors on nociception or paw 
edema, single injections of Y27632 or HA1077 were administered IPL 
to rat paws. As shown in Figure 1A and 1B, the lower doses of both 
ROCK inhibitors (25 μg/paw to 50 μg/paw) induced a decrease in 
the nociceptive threshold, equivalent to the development of hyper-
algesia, ie, a pronociceptive response. Intermediate doses were associ-
ated with no significant changes in nociceptive thresholds, whereas 
higher doses (500 μg/paw to 1000 μg/paw) were associated with an 
elevation of nociceptive threshold above basal levels, equivalent 
to hypoalgesia or an analgesic response. However, IPL administra-
tion of the same doses of Y27632 and HA1077 evoked a continuous 
dose-response curve of paw edema formation, as shown in Figure 2A 
and 2B, respectively. It is worth emphasizing that the edema measure-
ments were conducted in the same rats and at the same time as the 
nociceptive assays. The effects of a cGMP analogue given IPL on 
nociceptive threshold and paw edema were also studied. As shown in 
Figure 3, 8-bromo-cGMP also elicited a biphasic effect on nociceptive 
responses over the dose range used (25 μg to 1000 μg). However, the 
low dose of 8-bromo-cGMP (25 μg/paw) was associated with an eleva-
tion of nociceptive threshold above basal levels (hypoalgesia) whereas 
the highest dose (1000 μg/paw) was associated with a lowering of 
nociceptive thresholds (Figure 3). Moreover, the animals injected IPL 
with 8-bromo-cGMP showed no increases in paw volume, ie, no signs 
of paw edema (data not shown).
Treatments administered to the right ipsilateral hindpaw that 
altered its nociceptive threshold or volume had no effects on the 
responses in the left contralateral paw that received only vehicle 
(Table 1).
effects of Y27632 on responses to carrageenan in rat hindpaws
Because Y27632 administered alone altered the nociceptive threshold 
of rat paws, the effects of combining Y27632 with carrageenan, a stan-
dard proinflammatory stimulus (47), were subsequently examined. In 
these assays, Y27632 was injected IPL 5 min before carrageenan and 
nociceptive thresholds and paw volume measured over the subsequent 
180 min. At the lower dose, Y27632 (25 μg per paw) which, when 
given alone, induced significant hyperalgesia (Figure 1A), did not add 
to the hyperalgesia induced by carrageenan (Figure 4A) or modify its 
time course (data not shown). At the higher dose (500 μg), however, 
Y27632 did modify carrageenan-induced hyperalgesia, decreasing the 
fall of nociceptive threshold (Figure 4A), ie, the ROCK inhibitor 
behaved as an antinociceptive agent. Hindpaw volumes from these 
animals injected with carrageenan and Y27632 were also measured 
(Figure 4B). Again, the low dose of Y27632 did not affect carrageenan-
induced paw edema, whereas the higher dose of Y27632 clearly 
Figure 1) Dual effects of two Rho-kinase (ROCK) inhibitors, Y27632 
(a) and HA1077 (B), on nociceptive threshold in rats. Nociceptive 
thresholds were measured using a pressure algesimeter at 15 min, 30 min, 
60 min and 120 min following single injections in rat hind paws. Data 
were transformed into area under the curve (AUC) over 120 min. 
Inhibitors were prepared in a solution of dimethyl sulfoxide diluted in iso-
tonic saline: vehicle (Veh); Y27632 (Y), 2.5 μg to 1000 μg; HA1077 
(HA), 25 μg to 500 μg. *Significantly different from vehicle (P<0.01). 
n=4 to n=5 animals per group
Figure 2) Dose-response curve of Y27632 (Y) (a) and HA1077 (HA)
(B) on paw edema formation. The paw volumes (in mL) were measured 
using a plethysmometer (Ugo Basile, Italy) at 15 min, 30 min, 60 min and 
120 min following single injections in rat hindpaws. Inhibitors were prepared 
in a solution of dimethyl sulfoxide diluted in isotonic saline: vehicle (Veh); 
Y27632 (Y), 2.5 μg to 1000 μg; HA1077 (HA), 25 μg to 500 μg. 
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increased the carrageenan-induced edema. The cGMP analogue 
8-bromo-cGMP combined with carrageenan showed effects similar to 
those of Y27632 on carrageenan-induced hyperalgesia, with the lower 
dose of 8-bromo-cGMP (25 μg) producing an antinociceptive effect 
(data not shown).
effect of cytochalasin B on the pro- and antinociceptive effects of 
Y27632
Cytochalasin B is known as an inhibitor of actin filament polymeriza-
tion (49) and has recently been shown to be involved in analgesia 
induced by morphine in the pain model used in the present study (50). 
Local pretreatment of rat paws (15 min before) with cytochalasin B 
(1 μg IPL) did not affect hyperalgesia following the low dose of Y27632 
(25 μg) but completely prevented the hypoalgesia induced by the high 
dose (500 μg) (Figure 5). Pretreatment with cytochalasin B did not 
affect the paw edema induced by the ROCK inhibitor in these animals 
(data not shown).
DiScuSSioN
Our experiments showed that Y27632, a ROCK inhibitor, induced a 
dose-dependent biphasic effect on nociceptive response, ie, hyper- and 
hypoalgesia, when administered locally to rat hindpaws. Because both 
the biphasic nature of the response and the clear pronociceptive effect 
were unexpected, we used another ROCK inhibitor, HA1077, in our 
system. Over a similar dose range (25 μg to 500 μg per paw), HA1077 
also induced a decrease and an increase in nociceptive threshold, 
respectively, ie, hyperalgesia at the lowest dose and hypoalgesia at the 
highest dose used. Interestingly, we had previously shown that anal-
gesic drugs, such as celecoxib and morphine, also induced hypoalgesic 
or antinociceptive responses under similar experimental conditions 
(50-52). Because the molecular weight of the two ROCK inhibitors 
are very close (approximately 300), the doses we used were comparable 
in molar terms, and the similarity in responses to Y27632 or HA1077 
suggests that these biphasic nociceptive responses were more likely to 
be related to their common activity as ROCK inhibitors.
Our data are comparable with those reported by Chan et al (46), 
who used a model of cervical column transection, in that beneficial 
and detrimental effects, respectively, were also observed when a higher 
or a lower dose of Y27632 was used. However, the predominant effect 
associated with ROCK inhibitors was antinociception (14-17,53). In 
particular, HA1077 was associated with antinociceptive properties 
in a wide variety of pain models (18). In addition, another ROCK 
inhibitor (AS1892802) tested in a rat model of arthritis was similarly 
antinociceptive after oral (10 mg/kg) or intra-articular injection (3 μg) 
in inflamed knees (19,53). Yoshimi et al (20) observed no effect of this 
ROCK inhibitor, ie, neither nociception nor antinociception, after 
intra-articular injection in the noninflamed knee. One possible resolu-
tion to this paradox is to suggest that other kinases were inhibited by 
the doses of ROCK inhibitors that we were using (see below), that these 
other kinases were mediating these opposing effects and overcoming the 
pronociceptive effects of ROCK inhibition. Another possible solution, 
also suggested by Zulauf et al (17), is that ROCK, via microfilament 
modulation, has a role in the cGMP pathway, which has been described 
as inducing a biphasic effect on nociception (reviewed in Cury et al 
[45]). 
Indeed, the cGMP analogue (8-bromo-cGMP) used in the present 
study under the same experimental conditions as that of the ROCK 
inhibitors showed a biphasic nociceptive threshold response, clearly 
demonstrating a role for this pathway under our conditions. However, 
this cGMP analogue, which is an agonist of the NO/cGMP/PKG pain 
pathway, showed antinociceptive effects at low doses, compatible with 
earlier reports of the involvement of the cGMP pathway in analgesia 
(33,34,44). The pronociceptive effects of high doses of 8-bromo-
cGMP could be related to the pronociceptive effects reported for NO 
(43,44) or to effects of other unrelated systems. These data suggest that 
the NO/cGMP/PKG pathway may be involved in the antinociceptive 
effect of the ROCK inhibitors we studied.
Our results involving cytochalasin B demonstrated the dependence 
of the antinociceptive effect of ROCK inhibitors on cytoskeleton 
integrity, indicating the involvement of microfilaments in nociceptive 
pathways in the periphery. The present data are compatible with ear-
lier findings using cytochalasin B and the cyclooxygenase-2 inhibitor 
celecoxib and morphine (50). Because ROCK is a possible target for 
PKG (54) and ROCK activation can lead to modulation of actin fila-
ments and neurite outgrowth (17,55), it appears that ROCK and 
microfilaments in the cytoskeleton are important components of the 
modulation of peripheral pain. 
Figure 3) Dual effect of a cyclic (c)GMP analogue, 8-bromo-cGMP 
(8-B-cGMP) (25 μg to 1000 μg), on nociceptive thresholds in rat paws. 
Low doses of the cGMP analogue (25 μg) induced analgesia and higher 
doses induced hyperalgesia. *Significantly different from vehicle (P<0.01); 
n=4 animals per group. AUC Area under the curve; Veh Vehicle
Figure 4) Effects of the combination of Y27632 (Y) (25 μg or 500 μg) with 
carrageenan (CG) (250 μg) on rat hyperalgesia (a) and paw edema (B). 
The effects were assessed using a pressure algesimeter and a plethysmometer, 
respectively. Data were transformed to area under the curve (AUC) over 
180 min. #Significantly different from CG (vehicle [Veh]-CG); P<0.05. 
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One clear limitation to the present study is the specificity of the 
ROCK inhibitors. Signalling systems other than the ROCKs may be 
particularly relevant to the effects of high doses of ROCK inhibitors 
because both the inhibitors we have used, similar to most kinase inhib-
itors, are also inhibitors of kinases other than ROCK, usually with 
lower potencies. Thus, relative to ROCK, Y27632 has a half-maximal 
inhibitory concentration (IC50) 10-fold greater and HA1077 is 
approximately threefold less potent toward mitogen and stress acti-
vated kinase 1 (56). Potencies against protein kinase A or protein 
kinase C are also approximately 10- to 20-fold less than against 
ROCK, for both compounds (56). However, the IC50 values for 
ROCK inhibition range between 800 nM and 20 μM, concentrations 
well below those we have applied (78 nmol to 1560 nmol [25 μg to 
500 μg] in 100 μL), but there are factors that would further reduce this 
margin. First, the reported IC50 values have been determined in vitro 
with cell-free systems, and we applied the compounds to the foot pad, 
so there will be both diffusion and binding in the extracellular space 
and passage through the cell membrane to dilute and delay the 
amounts actually reaching an intracellular kinase. Also, the IC50 
measured using a whole-cell assay may be very different from that with 
cell-free enzymes. For instance, the IC50 for fasudil as an inhibitor of 
95D lung carcinoma cells in culture was 0.79 mg/mL (equivalent to 
2.1 mM [57]). Chan et al (46) used intrathecal infusions of 2 mM or 
20 mM repeated over 14 days to show the effects of Y27632 on rat 
spinal cord injury. Nevertheless, and in spite of the similarity of the 
hyperalgesic responses to the two different ROCK inhibitors, we can-
not exclude the possibility that the effects we observed were not caus-
ally related to inhibition of ROCK.
The present study used one model of inflammatory pain and one mode 
of stimulation; therefore, it is possible that in other peripheral pain mod-
els, such as IPL formalin (43) or rat arthritic knees (19,53), and using 
other stimuli, the effects of ROCK inhibitors could be different. However, 
we used a thermal stimulus (Hargreaves method) in our model with car-
rageenan inflammation (58) and obtained results in good agreement with 
those obtained with the mechanical stimulus we used here. It is also pos-
sible that the outcome of our experiments would be different in female rats 
because we used only male rats in the present study.
It is important to emphasize that even at the highest doses of the 
ROCK inhibitors, the contralateral paw that was not injected with 
Y27632 or HA1077 showed no changes in its nociceptive or edema 
status. This demonstrated very clearly that the effects we observed in the 
treated ipsilateral paw were, indeed, local effects and not due to leakage 
of the locally injected inhibitor into the systemic circulation. These data 
from the contralateral paw also serve to exclude the possibility of a cen-
tral or spinal (28,46) action of the ROCK inhibitors, leading to sedation 
and consequent motor dysfunction. In another model, alterations in the 
activation of the RhoA-ROCK system were associated with changes in 
conduction velocity only in sensory, not motor, neurons (59). 
An unexpected outcome of our experiments was that the ROCK 
inhibitors were inflammatory at the lower doses, when the compounds 
were most likely to be acting as selective inhibitors of ROCK. This action 
was expressed in our model as hyperalgesia (a pronociceptive effect), and 
the antinociceptive effects were only observed at the higher doses when 
selectivity would be less, even when the paw was inflamed by carrageenan. 
The proinflammatory effect of ROCK inhibition by Y27632 or HA1077 
was also expressed as increased microvascular permeability leading to the 
formation of edema. This component of inflammation was directly dose-
dependent, with no indication of a biphasic profile. Thus, at low doses, 
the ROCK inhibitors were primarily proinflammatory and only partially 
anti-inflammatory (in terms of pain) at the higher doses.
Our results have also contributed to the evidence for a mechanistic 
divergence between two classical components of inflammation – pain 
and edema. Both Y27632 and HA1077 clearly, and without any sign of 
a biphasic profile, induced paw edema dose-dependently, contrasting 
sharply with the biphasic effects on nociception. This division 
between edema and nociception in our model was emphasized by the 
effect of 8-bromo-cGMP, which elicited no signs of edema over a dose 
range that induced a biphasic effect on nociception. This discrepancy 
between the two inflammatory responses did, however, show very 
clearly that, in our model, changes in nociception and edema were 
coincident in time but were not mediated by the same pathways. 
Although these distinct pathways have not yet been fully elucidated, a 
similar separation has been observed earlier in our model (51) and 
under other experimental conditions (60). 
coNcLuSioN 
We have demonstrated that the peripheral injection of two ROCK 
inhibitors exerted a dual effect on nociceptive responses. Biphasic 
nociceptive responses were also induced by 8-bromo-cGMP, an activa-
tor of the NO/cGMP/PKG pathway. Our results are in agreement with 
most previous reports of antinociceptive effects of ROCK inhibitors 
but in contrast to their more frequently described anti-inflammatory 
activity. This difference is most likely to reflect the local and periph-
eral, as distinct from systemic, application of the ROCK inhibitors. 
Our data also suggested the possible involvement of the actin fila-
ments of the cytoskeleton in nociceptive responses, which was modu-
lated by ROCK inhibition. Further studies, at the molecular level are 
warranted to confirm the involvement of ROCKs and the NO/cGMP/
PKG pathway in the processes of peripheral nociception, in both 
inflamed and normal tissues. Such data, however, open new approaches 
to our understanding of the mechanisms involved in the genesis of 
pain at the structural level of the cells.
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Figure 5) Reversal of the analgesic effect induced by Y27632 (Y) (25 μg or 
500 μg) by cytochalasin B (CB) (1 μg) in rat paws. CB was injected 5 min 
before administration of a low (25 μg) or a high (500 μg) dose of Y locally. 
CB and Y were diluted in a solution of dimethyl sulfoxide and isotonic saline 
(vehicle [Veh]). #Significant difference between Veh-Y500 and CB-Y500 
(P<0.05). n=3 to n=5 animals per group
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